Rhythm Pharmaceuticals, Inc. (RYTM) stock
RYTMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 5/30265% above fair value
$115.02+5.16 (+4.70%)
Close on Nov 13, 2026Market cap $7.92BP/E –Yield –
Rhythm Pharmaceuticals r&d expenses
Research and development expenses are spending on new products and technology.
Rhythm Pharmaceuticals's R&D Expenses for the twelve months ending Jun 30, 2026 was $173.21M, up 9.4% year over year. For fiscal 2025 it was $167.34M, down 29.7% from the year before. Over ten years it grew 37.1% a year on average. The highest annual figure on record is $237.96M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $167.34M | -29.7% |
| FY2024 | Dec 31, 2024 | $237.96M | +76.3% |
| FY2023 | Dec 31, 2023 | $134.95M | +24.2% |
| FY2022 | Dec 31, 2022 | $108.63M | +4.3% |
| FY2021 | Dec 31, 2021 | $104.13M | +15.1% |
| FY2020 | Dec 31, 2020 | $90.45M | -17.4% |
| FY2019 | Dec 31, 2019 | $109.45M | +117.4% |
| FY2018 | Dec 31, 2018 | $50.34M | +119.9% |
| FY2017 | Dec 31, 2017 | $22.89M | +16.8% |
| FY2016 | Dec 31, 2016 | $19.59M | +174.1% |
| FY2015 | Dec 31, 2015 | $7.15M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $43.43M | +2.6% |
| Q1 FY2026 | Mar 31, 2026 | $41.73M | +12.9% |
| Q4 FY2025 | Dec 31, 2025 | $42.03M | +2.1% |
| Q3 FY2025 | Sep 30, 2025 | $46.03M | +21.3% |
| Q2 FY2025 | Jun 30, 2025 | $42.31M | +40.1% |
| Q1 FY2025 | Mar 31, 2025 | $36.97M | -71.3% |
| Q4 FY2024 | Dec 31, 2024 | $41.17M | +37.7% |
| Q3 FY2024 | Sep 30, 2024 | $37.93M | +13.0% |
| Q2 FY2024 | Jun 30, 2024 | $30.19M | -10.0% |
| Q1 FY2024 | Mar 31, 2024 | $128.67M | +239.1% |
| Q4 FY2023 | Dec 31, 2023 | $29.89M | +26.9% |
| Q3 FY2023 | Sep 30, 2023 | $33.57M | +59.0% |
| Q2 FY2023 | Jun 30, 2023 | $33.54M | +6.6% |
| Q1 FY2023 | Mar 31, 2023 | $37.95M | +16.7% |
| Q4 FY2022 | Dec 31, 2022 | $23.55M | -25.4% |
| Q3 FY2022 | Sep 30, 2022 | $21.12M | -23.3% |
| Q2 FY2022 | Jun 30, 2022 | $31.46M | +25.3% |
| Q1 FY2022 | Mar 31, 2022 | $32.51M | +63.3% |
| Q4 FY2021 | Dec 31, 2021 | $31.57M | +43.8% |
| Q3 FY2021 | Sep 30, 2021 | $27.54M | +19.8% |
| Q2 FY2021 | Jun 30, 2021 | $25.10M | +9.2% |
| Q1 FY2021 | Mar 31, 2021 | $19.91M | -11.5% |
| Q4 FY2020 | Dec 31, 2020 | $21.95M | -11.5% |
| Q3 FY2020 | Sep 30, 2020 | $23.00M | -13.5% |
| Q2 FY2020 | Jun 30, 2020 | $23.00M | -34.9% |
| Q1 FY2020 | Mar 31, 2020 | $22.50M | -1.1% |
| Q4 FY2019 | Dec 31, 2019 | $24.81M | +32.2% |
| Q3 FY2019 | Sep 30, 2019 | $26.57M | +148.2% |
| Q2 FY2019 | Jun 30, 2019 | $35.31M | +311.3% |
| Q1 FY2019 | Mar 31, 2019 | $22.76M | +85.3% |
| Q4 FY2018 | Dec 31, 2018 | $18.76M | +182.0% |
| Q3 FY2018 | Sep 30, 2018 | $10.71M | +79.3% |
| Q2 FY2018 | Jun 30, 2018 | $8.58M | +59.1% |
| Q1 FY2018 | Mar 31, 2018 | $12.29M | +152.1% |
| Q4 FY2017 | Dec 31, 2017 | $6.65M | +18.1% |
| Q3 FY2017 | Sep 30, 2017 | $5.97M | +10.2% |
| Q2 FY2017 | Jun 30, 2017 | $5.40M | – |
| Q1 FY2017 | Mar 31, 2017 | $4.87M | – |
| Q4 FY2016 | Dec 31, 2016 | $5.63M | – |
| Q3 FY2016 | Sep 30, 2016 | $5.42M | – |
See a number that looks wrong?